 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12345678910111213...1920» |
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) (clinicaltrials.gov) - Sep 19, 2024
P3, N=230, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion date, Trial initiation date: SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=470, Not yet recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial completion date: Sep 2024 --> Sep 2025 | Initiation date: Feb 2024 --> Sep 2024
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. (Pubmed Central) - Sep 18, 2024
In participants with obesity, once-daily oral semaglutide 50?mg reduced energy intake, body weight and appetite, and improved control of eating. There was no evidence of delayed gastric emptying at week 20, as measured through paracetamol absorption.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Journal: Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching. (Pubmed Central) - Sep 18, 2024
In this study, including obese participants with poor glycaemic control, switching DPP-4 inhibitors to oral semaglutide showed more beneficial effects on both glycaemic and weight control, irrespective of age, body weight and diabetes duration. Therefore, we should bear in mind that it would be better to start using an oral semaglutide in clinical practice, particularly in obese participants with poor glycaemic control with DPP-4 inhibitors.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
P1/2 data, P3 data, Journal, Monotherapy: Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. (Pubmed Central) - Sep 18, 2024
P3
Oral semaglutide resulted in significantly greater reductions in HbA1c across all doses and in significant body weight reductions for the 7 mg and 14 mg doses when compared with placebo in predominantly Chinese participants with type 2 diabetes insufficiently controlled by diet and exercise alone. Oral semaglutide was generally well tolerated, with a safety profile consistent with that seen in the global PIONEER trials.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
P1/2 data, P3 data, Journal: Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. (Pubmed Central) - Sep 18, 2024
P3
Significantly greater reductions in both HbA1c and body weight over 26 weeks were seen with oral semaglutide 3 mg, 7 mg and 14 mg than with sitagliptin 100 mg in a predominantly Chinese population with type 2 diabetes inadequately controlled with metformin treatment. Oral semaglutide was generally well tolerated, with a safety profile consistent with that seen in the global PIONEER trials.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Preclinical, Journal: Semaglutide ameliorated autism-like behaviors and DNA repair efficiency in male BTBR mice by recovering DNA repair gene expression. (Pubmed Central) - Sep 15, 2024
Furthermore, we elucidated the underlying mechanism(s) responsible for the ameliorative effects of semaglutide against behavioral problems and DNA repair deficiency in BTBR mice...Semaglutide restored the disrupted DNA damage/repair pathways in the BTBR mice by reducing Gadd45a expression and increasing Ogg1 and Xrcc1 expression at both the mRNA and protein levels. This suggests that semaglutide holds great potential as a novel therapeutic candidate for treating ASD traits.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. (Pubmed Central) - Sep 14, 2024
While questions about long-term infant outcomes, the safety of maternal nutrient intake, and the nutrient content of breast milk remain, our findings suggest that semaglutide concentrations in human milk are unlikely to pose clinical concerns for breastfed infants. These results support healthcare providers in making informed decisions regarding postpartum therapeutic interventions.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Real-world evidence, Real-world: Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. (Pubmed Central) - Sep 14, 2024
The oral formulation of semaglutide demonstrated equivalent effectiveness in glucose control and body weight management in patients with T2DM and CKD, even with a higher proportion of patients receiving low to medium doses. Gastrointestinal side effects were comparable between both oral and subcutaneous formulations.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Review, Journal: Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis. (Pubmed Central) - Sep 12, 2024
Gastrointestinal side effects were comparable between both oral and subcutaneous formulations. Treatment with semaglutide combined with metformin significantly improved glycemic control, insulin resistance, weight, BMI, and lipid profiles in patients with T2DM who are overweight or obese.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Preclinical, Journal: The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis. (Pubmed Central) - Sep 10, 2024
Treatment with semaglutide combined with metformin significantly improved glycemic control, insulin resistance, weight, BMI, and lipid profiles in patients with T2DM who are overweight or obese. Osteoporosis was induced in female rats by ovariectomy, and the ovariectomized rats were treated with alendronate as standard treatment with a dose of 3
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Real-world evidence, Real-world: Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program. (Pubmed Central) - Sep 9, 2024
Consistent with clinical trial findings, this real-world data analysis showed that semaglutide was well tolerated and that, for a large population, it effectively reduced BMI, body weight and HbA1c, albeit to smaller magnitudes than observed in clinical trials. These findings provide valuable insights into real-world experience and the long-term effectiveness of semaglutide.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, Real-world evidence, Adherence, Real-world: Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data. (Pubmed Central) - Sep 7, 2024
The hazard ratio for treatment discontinuation, using O-SEMA as the reference, was 1.45 for SEMA-SC, although the discontinuation rate of O-SEMA was higher during the early stage. O-SEMA initiators showed significantly higher adherence and greater persistence in therapy than SEMA-SC initiators at 12?months, which could lead to earlier initiation of GLP-1RA treatment.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Review, Journal: Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis. (Pubmed Central) - Sep 5, 2024
Semaglutide was associated with a reduced risk of AF occurrence in the overall analysis. Favorable outcomes were observed in subsets using other antihyperglycemic medications as controls, in patients with T2DM, and with oral semaglutide.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Phase classification: SemaFatCard: Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction (clinicaltrials.gov) - Sep 5, 2024
P4, N=88, Not yet recruiting, Sponsor: University of Sao Paulo General Hospital
Favorable outcomes were observed in subsets using other antihyperglycemic medications as controls, in patients with T2DM, and with oral semaglutide. Phase classification: P3 --> P4
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Journal: Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study. (Pubmed Central) - Sep 3, 2024
Phase classification: P3 --> P4 Oral semaglutide treatment for T2DM in patients with MASLD leads to an improvement in liver steatosis and injury, surrogate markers of fibrosis, diabetic status, and lipid profile, and reduces body weight.
- ||| Journal, Adverse events, Serious adverse event: Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System. (Pubmed Central) - Sep 2, 2024
Conclusion This pharmacovigilance study utilizing the FAERS database identified potential safety signals of increased mortality and serious AE reporting associated with certain GLP-1RAs, particularly the earlier approved liraglutide agents Byetta and Victoza. These findings highlight the importance of proactive postmarket surveillance to characterize the real-world safety profiles of individual GLP-1RA drugs.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Preclinical, Journal: Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease. (Pubmed Central) - Sep 1, 2024
These changes were associated with increased activation of the endothelial-protective AMPK pathway (p=0.005), coupled with downstream increases in endothelial nitric oxide synthase (p=0.014). This study is the first to reveal the capacity of oral semaglutide to augment cardiac function in the chronically ischemic heart in a highly translational large animal model, likely through AMPK-mediated improvement in endothelial function and perfusion to the ischemic myocardium.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide. (Pubmed Central) - Aug 31, 2024
Herein, we describe the first case of skin-limited LCV induced by once-weekly subcutaneous semaglutide in a 73-year-old man with T2DM, who experienced the complete resolution of the skin lesions shortly after the discontinuation of semaglutide therapy. Future prospective studies, adverse event reporting and post-marketing surveillance will certainly contribute to establishing if LCV represents a less rare than expected side effect of both oral and subcutaneous semaglutide formulations.
- ||||| AZD5004 / AstraZeneca
New P2 trial: SOLSTICE: Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Aug 30, 2024
P2, N=384, Not yet recruiting, Sponsor: AstraZeneca
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial. (Pubmed Central) - Aug 28, 2024
Despite the non-significant difference in NAFLD fibrosis score (NFS) (p-value = 0.45 and 0.63), group II had significantly lower scores of the fibrosis-4 score (FIB-4), liver stiffness measurement (LSM), and controlled attenuation parameter (CAP) at 6 and 12 months (p-value < 0.001). Semaglutide improves lipid profile, liver steatosis, and fibrosis parameters and reduces the BMI in T2D and obese patients with NAFLD.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Elucidating the Degradation Pathways of Human Insulin in the Solid State. (Pubmed Central) - Aug 26, 2024
Semaglutide improves lipid profile, liver steatosis, and fibrosis parameters and reduces the BMI in T2D and obese patients with NAFLD. While there have been significant advances in the development of peptide oral dosage forms in recent years, highlighted by the clinical and commercial success of approved peptides such as Rybelsus
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide. (Pubmed Central) - Aug 23, 2024
A subsequent clinical evaluation revealed no abnormalities on macular optical coherence tomography, fundus photography, fundus autofluorescence or Humphrey visual field. This case of a bilateral central scotoma under scotopic conditions that resolved after medication discontinuation expands the knowledge of potential side effects from this increasingly popular diabetic and weight loss medication.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial. (Pubmed Central) - Aug 23, 2024
PPIE is integral in ASCEND PLUS and will continue throughout the trial. This involvement has been critical to optimising the trial design, successfully obtaining regulatory and ethical approval, and conducting the trial.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Real-world evidence, Real-world: PIONEER REAL Japan: Primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type?2 diabetes in Japanese clinical practice. (Pubmed Central) - Aug 22, 2024
This involvement has been critical to optimising the trial design, successfully obtaining regulatory and ethical approval, and conducting the trial. In routine clinical practice, HbA1c and bodyweight were significantly reduced from baseline in adults initiating oral semaglutide, including those aged ?75?years, with no new safety concerns.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Comment on Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double?Blind Single?Centre Study. (Pubmed Central) - Aug 21, 2024
In routine clinical practice, HbA1c and bodyweight were significantly reduced from baseline in adults initiating oral semaglutide, including those aged ?75?years, with no new safety concerns. No abstract available
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial, New P4 trial: SemaFatCard: Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction (clinicaltrials.gov) - Aug 16, 2024
P3, N=88, Not yet recruiting, Sponsor: University of Sao Paulo General Hospital
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Hot Water Eliminates the Bitter Taste of Oral Semaglutide: A Report of Four Cases. (Pubmed Central) - Aug 14, 2024
No abstract available When the hot water temperature was increased to above 46.0
- || Review, Journal: Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes. (Pubmed Central) - Aug 13, 2024
When the hot water temperature was increased to above 46.0 No abstract available
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder (clinicaltrials.gov) - Aug 13, 2024
P2, N=72, Active, not recruiting, Sponsor: University Health Network, Toronto
No abstract available Recruiting --> Active, not recruiting
- || metopimazine (NG101) / Neurogastrx
Enrollment closed, Adverse events: A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist (clinicaltrials.gov) - Aug 12, 2024
P2, N=120, Active, not recruiting, Sponsor: Neurogastrx, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study. (Pubmed Central) - Aug 8, 2024
The mathematical model based on the meta-analysis predicts that the SOUL study on oral semaglutide will be terminated early, with oral semaglutide showing benefits in terms of MACE compared to placebo. If the SOUL study corroborates the findings of this model, it may not only form the basis for the calculation of power but also define the duration of such studies, reducing costs and easing the process of designing cardiovascular outcome trials (CVOTs).
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Retrospective data, Journal: Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 (Pubmed Central) - Aug 7, 2024
If the SOUL study corroborates the findings of this model, it may not only form the basis for the calculation of power but also define the duration of such studies, reducing costs and easing the process of designing cardiovascular outcome trials (CVOTs). Escalating the dose of oral semaglutide to 14
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, FDG PET: FDG PET in a Patient on a GLP-1 Agonist/Insulin Secretagogue. (Pubmed Central) - Aug 5, 2024
Clinicians should be aware of the presence of these drugs and their potential effect on biodistribution in FDG PET. Further study is needed to best understand the effects of these medications on FDG biodistribution.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus. (Pubmed Central) - Aug 5, 2024
Switching from a DPP-4i to oral semaglutide may be useful for Japanese patients with T2D who have inadequate glycemic or BW control. However, its utility may be limited by gastrointestinal adverse effects in certain patients.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial initiation date, Adherence: DIACRON: The Effect of Adherence to Oral Semaglutide on Glycaemic Control in People With Type 2 Diabetes Treated With Metformin (clinicaltrials.gov) - Jul 30, 2024
P=N/A, N=20, Recruiting, Sponsor: Aalborg University Hospital
However, its utility may be limited by gastrointestinal adverse effects in certain patients. Initiation date: May 2024 --> Nov 2023
- | Rybelsus (semaglutide oral) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Retrospective data, Journal: Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial. (Pubmed Central) - Jul 30, 2024
P4
Further, we found a decrease in TKV in all active treatment groups, which was possibly mediated by a reduction in hyperfiltration. Our findings suggest that DWI-MRI may serve as a promising tool for investigating the underlying mechanisms of medical interventions in individuals with type 2 diabetes but may reflect effects not related to fibrosis.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Journal: New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. (Pubmed Central) - Jul 27, 2024
The superior metabolic effects of semaglutide, correlated to dapagliflozin, may contribute to a more efficient decrease in hepatic stress and injury, leading to a substantial enhancement of liver function in T2DM patients. Further investigations conducted over an ideal timeframe are necessary to confirm the evidence presented in this study.
- Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Retrospective data, Journal: Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study). (Pubmed Central) - Jul 26, 2024
Further investigations conducted over an ideal timeframe are necessary to confirm the evidence presented in this study. Oral semaglutide improves the glycemic control of older subjects, but it might be a risk for potential hypoglycemia and discontinuation because of adverse events in subjects of???75
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Enrollment change, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 25, 2024
P=N/A, N=50, Completed, Sponsor: Novo Nordisk A/S
Oral semaglutide improves the glycemic control of older subjects, but it might be a risk for potential hypoglycemia and discontinuation because of adverse events in subjects of???75 Enrolling by invitation --> Completed | N=194 --> 50
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: PIONEER REAL: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice (clinicaltrials.gov) - Jul 25, 2024
P=N/A, N=194, Completed, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Completed | N=194 --> 50 Recruiting --> Completed
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Review, Journal: Semaglutide and obesity: beyond the nutritional and lifestyle intervention? (Pubmed Central) - Jul 19, 2024
Data in the literature on the anti-obesity action of semaglutide are available for both routes of administration of the drug, with a prevalence of studies using the s.c. one. However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field.
- Rybelsus (semaglutide oral) / Novo Nordisk
EFFICACY AND SAFETY OF ORAL SEMAGLUTIDE IN COMBINATION WITH DIETARY AND LIFESTYLE MODIFICATIONS FOR OVERWEIGHT OR OBESITY: A RANDOMIZED CONTROLLED TRIAL (OSO STUDY (Lehar 1) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2178;
P4
However, given its dosage, oral semaglutide may provide greater attractiveness and better treatment adherence, but further research is needed in this field. In adults with overweight or obesity but without type 2 diabetes, oral Semaglutide combined with dietary and lifestyle modifications resulted in a significant and clinically meaningful reduction in body weight compared to dietary and lifestyle modifications alone.
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
New trial, Real-world evidence, Real-world effectiveness, Real-world: REALISED: Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes (clinicaltrials.gov) - Jul 18, 2024
P=N/A, N=209, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Surgery, Metastases: FLAMES: Fibrosis Lessens After Metabolic Surgery (clinicaltrials.gov) - Jul 18, 2024
P4, N=120, Recruiting, Sponsor: Ali Aminian
In adults with overweight or obesity but without type 2 diabetes, oral Semaglutide combined with dietary and lifestyle modifications resulted in a significant and clinically meaningful reduction in body weight compared to dietary and lifestyle modifications alone. Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Phase classification, Surgery, Metastases: FLAMES: Fibrosis Lessens After Metabolic Surgery (clinicaltrials.gov) - Jul 16, 2024
P4, N=120, Not yet recruiting, Sponsor: Ali Aminian
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P4
- |||| metopimazine (NG101) / Neurogastrx
New P2 trial, Adverse events: A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist (clinicaltrials.gov) - Jul 14, 2024
P2, N=150, Recruiting, Sponsor: Neurogastrx, Inc.
- || Rybelsus (semaglutide oral) / Novo Nordisk
Review, Journal, HEOR, Real-world evidence, Real-world: Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence. (Pubmed Central) - Jul 13, 2024
Oral semaglutide exhibited a reasonable reduction in HbA1c and weight in people with T2D, consistent with the findings from PIONEER trials. While no new safety issues emerged, the inherent limitations of RWS underscore the necessity of long-term investigations to comprehensively assess safety.
- ||||| orforglipron (OWL833) / Eli Lilly
Enrollment closed: ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (clinicaltrials.gov) - Jul 12, 2024
P3, N=1576, Active, not recruiting, Sponsor: Eli Lilly and Company
While no new safety issues emerged, the inherent limitations of RWS underscore the necessity of long-term investigations to comprehensively assess safety. Recruiting --> Active, not recruiting
- || Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
PK/PD data, Review, Journal: Clinical Pharmacokinetics of Semaglutide: A Systematic Review. (Pubmed Central) - Jul 2, 2024
Food and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure...The existing pharmacokinetic data can assist in developing and evaluating pharmacokinetic models of semaglutide and will help clinicians predict semaglutide dosages. In addition, it can also help optimize future clinical trials.